期刊文献+

慢性粒细胞白血病慢性期与急变期基因表达差异的研究 被引量:5

Study of gene expression profile of chronic myeloid leukemia in chronic and blastic phases
原文传递
导出
摘要 目的 研究慢性粒细胞白血病 (CML)不同临床阶段的基因表达差异 ,为阐明CML演变的可能机制提供依据。方法 应用DNA芯片技术 ,对CML慢性期与急变期骨髓单个核细胞的基因表达差异进行了检测。结果 在检测的 1176个基因中 ,有 6 8个基因显示急变期较慢性期明显上调 ,其中转录因子 16个 (2 3.5 % ) ,细胞表面抗原 15个 (2 2 .1% ) ,细胞调节蛋白 13个 (19.1% ) ,其它 2 4个(35 3% )。在差异表达的基因中 ,有 17个基因仅在急变期表达 ,而在慢性期不表达 ,11个 (16 .2 % )与G蛋白基因有关。结论 CML慢性期与急变期骨髓单个核细胞基因表达谱存在显著差异 ,基因高表达是CML急变期的特征之一。G蛋白相关基因在CML急变过程中可能起着重要作用。 Objective To study the gene expression profile of chronic myeloid leukemia(CML) in chronic and blast phases for providing information about the potential mechanisms of blastic crisis. Methods The gene expression difference of bone marrow mononuclear cells between CML in chronic and in blastic phases was examined with DNA array. Results In the blastic phase,68 genes were obviously up-regulated in the 1176 tested genes. Among the 68 genes,the transcription factors accounted for 23.5%,cell surface antigens 22.1%,regulation proteins 19.1% and others 35.3%. There were 17 genes expressed only in the blastic phase and 11(16.2%) genes related to G protein. Conclusions Obvious difference of gene expression profile existed between chronic and blastic phases of CML. Up-regulation of gene expression is one of the characteristics of CML in blastic phase. The genes related to G protein may play an important role in the blastic transformation of CML.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2004年第3期167-170,共4页 Chinese Journal of Hematology
基金 国家自然科学基金资助项目 (3 0 2 714 63 )
关键词 慢性粒细胞白血病 临床分期 基因表达 DNA芯片技术 单个核细胞 Leukemia,myeloid,chronic DNA array Gene expression profile
  • 相关文献

参考文献1

  • 1(美)J.萨姆布鲁克(J.Sambrook)等著,金冬雁等.分子克隆实验指南[M]科学出版社,1992.

同被引文献72

  • 1何军,薛永权,李建琴,何海龙,何亚香,黄益萍,柴忆欢,朱伶俐.多重RT-PCR技术联合染色体核型分析在儿童急性淋巴细胞白血病诊断分型中的应用[J].中华血液学杂志,2004,25(7):413-416. 被引量:16
  • 2朱旭贞,虞瑛姿,方永明,梁赟,吕庆华,徐荣臻.酪氨酸蛋白磷酸酶2高表达对p210bcr/abl诱导的慢性粒细胞白血病细胞增殖与凋亡抵抗的影响[J].中华医学杂志,2005,85(27):1903-1906. 被引量:3
  • 3王玮,孙秉中,药立波,刘新平.酪氨酸激酶抑制剂STI571治疗慢性粒细胞白血病的研究[J].实用医学杂志,2005,21(19):2108-2111. 被引量:1
  • 4An X, Tiwari AK, Sun Y, et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review[J]. Leuk Res, 2010, 34(10): 1255-68.
  • 5Klener R Klener P Jr. ABLI, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy[J]. Klin Onkol, 2010, 23(4): 203-9.
  • 6Cui XS, Li XY, Shen XH, et al. Transcription profile in mouse four-cell, morula, and blastocyst: Genes implicated in compaction and blastocoel formation[J]. Mol Reprod Dev, 2007, 74(2): 133-43.
  • 7Frisch M, Klocke B, Haltmeier M, et al. Litlnspector: literalure and signal transduction pathway mining in PubMed abstracts [J]. Nucleic Acids Res, 2009, 37(Web Server issue): W135-40.
  • 8Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells[J]. Cancer Sci, 2010, 101(7): 1577-81.
  • 9Santos FP, Ravandi F. Advances in treatment of chronic myelogenous leukemia-new treatment options with tyrosine kinase inhibitors [J]. Leuk Lymphoma, 2009, 50 (Suppl 2): 16-26.
  • 10Nicholls SE, Lucas G, Graham G J, et al. Macrophage-inflammatory protein-lalpha receptor expression on normal and chronic myeloid leukemia CD34+ cells[J]. J Immunol, 1999, 162( 10): 6191-9.

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部